Compared to DMSO-only control treatment, tp53-/- + TP53C176F-expressing ERMS treated with ZMC1 showed a significant reduction in tumor growth over time (Figure 4—figure supplement 2D and G; p=0.0116 at week 3). This evidence concerns the gene TP53 and neoplasm.